Cargando…
Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine
OBJECTIVE: To clarify the effects of smoking on the disposition of two commonly used antipsychotics, olanzapine and clozapine, and to create standards to adjust the doses of these drugs in clinical practice based on the smoking status. DESIGN: A meta-analysis was conducted by searching MEDLINE, Scop...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948577/ https://www.ncbi.nlm.nih.gov/pubmed/24595134 http://dx.doi.org/10.1136/bmjopen-2013-004216 |
_version_ | 1782306791697154048 |
---|---|
author | Tsuda, Yoshiyuki Saruwatari, Junji Yasui-Furukori, Norio |
author_facet | Tsuda, Yoshiyuki Saruwatari, Junji Yasui-Furukori, Norio |
author_sort | Tsuda, Yoshiyuki |
collection | PubMed |
description | OBJECTIVE: To clarify the effects of smoking on the disposition of two commonly used antipsychotics, olanzapine and clozapine, and to create standards to adjust the doses of these drugs in clinical practice based on the smoking status. DESIGN: A meta-analysis was conducted by searching MEDLINE, Scopus and the Cochrane Library for relevant prospective and retrospective studies. INCLUDED STUDIES: We included the studies that investigated the effects of smoking on the concentration to dose (C/D) ratio of olanzapine or clozapine. PRIMARY OUTCOME MEASURE: The weighted mean difference was calculated using a DerSimonian-Laird random effects model, along with 95% CI. RESULTS: Seven association studies, comprising 1094 patients (652 smokers and 442 non-smokers) with schizophrenia or other psychiatric disorders, were included in the meta-analysis of olanzapine. The C/D ratio was significantly lower in smokers than in non-smokers (p<0.00001), and the mean difference was −0.75 (ng/mL)/(mg/day) (95% CI −0.89 to −0.61). Therefore, it was estimated that if 10 and 20 mg/day of olanzapine would be administered to smokers, about 7 and 14 mg/day, respectively, should be administered to non-smokers in order to obtain the equivalent olanzapine concentration. Four association studies of clozapine were included in the meta-analysis of clozapine, comprising 196 patients (120 smokers and 76 non-smokers) with schizophrenia or other psychiatric disorders. The C/D ratio was significantly lower in smokers than in non-smokers (p<0.00001), and the mean difference was −1.11 (ng/mL)/(mg/day) (95% CI −1.53 to −0.70). Therefore, it was estimated that if 200 and 400 mg/day of clozapine would be administered to smokers, about 100 and 200 mg/day, respectively, should be administered to non-smokers. CONCLUSIONS: We suggest that the doses of olanzapine and clozapine should be reduced by 30% and 50%, respectively, in non-smokers compared with smokers in order to obtain an equivalent olanzapine or clozapine concentration. |
format | Online Article Text |
id | pubmed-3948577 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-39485772014-03-12 Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine Tsuda, Yoshiyuki Saruwatari, Junji Yasui-Furukori, Norio BMJ Open Pharmacology and Therapeutics OBJECTIVE: To clarify the effects of smoking on the disposition of two commonly used antipsychotics, olanzapine and clozapine, and to create standards to adjust the doses of these drugs in clinical practice based on the smoking status. DESIGN: A meta-analysis was conducted by searching MEDLINE, Scopus and the Cochrane Library for relevant prospective and retrospective studies. INCLUDED STUDIES: We included the studies that investigated the effects of smoking on the concentration to dose (C/D) ratio of olanzapine or clozapine. PRIMARY OUTCOME MEASURE: The weighted mean difference was calculated using a DerSimonian-Laird random effects model, along with 95% CI. RESULTS: Seven association studies, comprising 1094 patients (652 smokers and 442 non-smokers) with schizophrenia or other psychiatric disorders, were included in the meta-analysis of olanzapine. The C/D ratio was significantly lower in smokers than in non-smokers (p<0.00001), and the mean difference was −0.75 (ng/mL)/(mg/day) (95% CI −0.89 to −0.61). Therefore, it was estimated that if 10 and 20 mg/day of olanzapine would be administered to smokers, about 7 and 14 mg/day, respectively, should be administered to non-smokers in order to obtain the equivalent olanzapine concentration. Four association studies of clozapine were included in the meta-analysis of clozapine, comprising 196 patients (120 smokers and 76 non-smokers) with schizophrenia or other psychiatric disorders. The C/D ratio was significantly lower in smokers than in non-smokers (p<0.00001), and the mean difference was −1.11 (ng/mL)/(mg/day) (95% CI −1.53 to −0.70). Therefore, it was estimated that if 200 and 400 mg/day of clozapine would be administered to smokers, about 100 and 200 mg/day, respectively, should be administered to non-smokers. CONCLUSIONS: We suggest that the doses of olanzapine and clozapine should be reduced by 30% and 50%, respectively, in non-smokers compared with smokers in order to obtain an equivalent olanzapine or clozapine concentration. BMJ Publishing Group 2014-03-04 /pmc/articles/PMC3948577/ /pubmed/24595134 http://dx.doi.org/10.1136/bmjopen-2013-004216 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Pharmacology and Therapeutics Tsuda, Yoshiyuki Saruwatari, Junji Yasui-Furukori, Norio Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
title | Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
title_full | Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
title_fullStr | Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
title_full_unstemmed | Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
title_short | Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
title_sort | meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine |
topic | Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948577/ https://www.ncbi.nlm.nih.gov/pubmed/24595134 http://dx.doi.org/10.1136/bmjopen-2013-004216 |
work_keys_str_mv | AT tsudayoshiyuki metaanalysistheeffectsofsmokingonthedispositionoftwocommonlyusedantipsychoticagentsolanzapineandclozapine AT saruwatarijunji metaanalysistheeffectsofsmokingonthedispositionoftwocommonlyusedantipsychoticagentsolanzapineandclozapine AT yasuifurukorinorio metaanalysistheeffectsofsmokingonthedispositionoftwocommonlyusedantipsychoticagentsolanzapineandclozapine |